The first day of the week demonstrated various market indexes: DJIA -0.10%, NASDAQ: + 0.14%, S & P500 -0.04%. Biotech showed a slight increase: NASDAQ Biotechnology (^ NBI) + 0.49%.
The excellent growth showed: Ultragenyx Pharmaceutical Inc. (RARE) + 10.44%, bluebird bio, Inc. (BLUE) + 10.61%, Collegium Pharmaceutical, Inc. (COLL) 10.10%, Pacira Pharmaceuticals, Inc. (PCRX) + 7.44%, Aquinox Pharmaceuticals Inc. (AQXP) + 19.83%. MannKind Corp. (MNKD) continued its growth (+ 10.30%).
Shares slumped for Neos Therapeutics, Inc. (NEOS) -19.88%, Enanta Pharmaceuticals, Inc. (ENTA) -8.40% and Avalanche Biotechnologies, Inc. (AAVL) -13.00%.
Today Aquinox Pharmaceuticals Inc. (AQXP) increased at once $ 2.08 (+ 19.83%)! The trading volume was 602,000 shares, instead of the average 266,000. The company’s capitalization is $ 216 million. The minimum share price during last52 weeks: $ 1.38, while the maximum — $ 55.75.
Aquinox Pharmaceuticals Inc. — biopharmaceutical company engaged in the discovery and development targeted treatments in the area of inflammatory and
IVAO ratings for Aquinox:
Science Rating: 
Financial Rating:
Total rating:
Aquinox’s leading drug candidate is AQ
Last year, the company’s EBITDA was — $ 23.44 million. Cash on balanced account: $ 117.4 million, which allows to work quietly for 5 years, considering the operating costs (cash flow: — $ 23,79 million).
Our forecast for stock prices: $ 16.
Learn how to invest in this company. Our experts will provide you all necessary support. Submit your application.
You can order more detailed analysis on the company, which includes:
- Analysis of financial performance
- Overview of the market and competitors
- Selection panel of experts on the drug and other drug companies
- Estimation of prospects of subsequent phases of testing
Buy analytical review or contact our sales department:
Phone: +7 812 332 20 08
IVAO analysts: Andrew Voronkov, Ph. D., Alexander Novikov, MBA.
